{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:14:54Z","timestamp":1789776894551,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a SA Malgrat de Mar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019717","name":"AstraZeneca Pharmaceutical Spain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-19-20449"],"award-info":[{"award-number":["ESR-19-20449"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["D081FL00007"],"award-info":[{"award-number":["D081FL00007"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmogo.2025.100187","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:54:33Z","timestamp":1748354073000},"page":"100187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry"],"prefix":"10.1016","volume":"8","author":[{"given":"A.J.","family":"Mu\u00f1oz Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-5383","authenticated-orcid":false,"given":"F.","family":"Castet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8859-5881","authenticated-orcid":false,"given":"J.","family":"Soto Alsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-4120","authenticated-orcid":false,"given":"J.","family":"Adeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Peinado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Al\u00e9s D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Rodr\u00edguez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lobo de Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-3147","authenticated-orcid":false,"given":"R.","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7440-9309","authenticated-orcid":false,"given":"I.","family":"Ruiz de Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ortega Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2025.100187_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s11523-024-01086-5","article-title":"The epidemiology of biliary tract cancer and associated prevalence of MDM2 amplification: a targeted literature review","volume":"19","author":"Kratz","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/OTT.S440979","article-title":"Efficacy and safety of the MDM2\u2013p53 antagonist brigimadlin (BI 907828) in patients with advanced biliary tract cancer: a case series","volume":"17","author":"Yamamoto","year":"2024","journal-title":"OncoTargets Ther"},{"issue":"20","key":"10.1016\/j.esmogo.2025.100187_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/14796694.2024.2340959","article-title":"Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians\u2019 and patients\u2019 perspectives","volume":"20","author":"Shroff","year":"2024","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100187_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"Jain","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib5","article-title":"Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by the EORTC GI Tract Cancer Group","volume":"3","author":"Fulgenzi","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100187_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1756283X17698090","article-title":"The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer","volume":"10","author":"Lee","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100187_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tranon.2016.01.007","article-title":"Genomic alterations in biliary tract cancer using targeted sequencing","volume":"9","author":"Yoo","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib8","article-title":"New perspectives in biliary tract cancers","volume":"5","author":"Goetze","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib9","article-title":"Targeted therapies in biliary tract cancer\u2014when precision becomes imprecise","volume":"5","author":"O\u2019Rourke","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib10","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100187_bib11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib12","article-title":"Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey","volume":"5","author":"Alsina","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2025.100187_bib13","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100187_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100187_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12935-024-03356-8","article-title":"MDM2: current research status and prospects of tumor treatment","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.esmogo.2025.100187_bib16","article-title":"Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry","volume":"7","author":"Macarulla","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib17","series-title":"Foundation Medicine. FoundationOne\u00aeCDx","year":"2024"},{"key":"10.1016\/j.esmogo.2025.100187_bib18","doi-asserted-by":"crossref","first-page":"v810","DOI":"10.1093\/annonc\/mdz269.044","article-title":"VHIO-300 and a thousand and one nights: a tale of precision medicine","volume":"30","author":"Carat\u00f9","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100187_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00235","article-title":"Analysis of MDM2 amplification: next-generation sequencing of patients with diverse malignancies","author":"Kato","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmogo.2025.100187_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100910","article-title":"Genomics driven precision oncology in advanced biliary tract cancer improves survival","volume":"42","author":"Kumar-Sinha","year":"2023","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100187_bib22","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.31862","article-title":"Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1\/programmed death-ligand 1 blockade responses","volume":"74","author":"Yoon","year":"2021","journal-title":"Hepatology"},{"issue":"69","key":"10.1016\/j.esmogo.2025.100187_bib23","doi-asserted-by":"crossref","first-page":"33232","DOI":"10.18632\/oncotarget.26075","article-title":"Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic","volume":"9","author":"Dembla","year":"2018","journal-title":"Oncotarget"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:25:49Z","timestamp":1762651549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819825000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":22,"alternative-id":["S2949819825000561"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100187","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100187"}}